Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 509
- Registration Number
- NCT05740566
- Locations
- 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Locations
- 🇨🇳
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Neoplasms, Ovarian
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 90
- Registration Number
- NCT05613088
- Locations
- 🇺🇸
Local Institution - 0065, Sacramento, California, United States
🇺🇸Local Institution - 0025, San Francisco, California, United States
🇺🇸Local Institution - 0061, Columbus, Ohio, United States
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Conditions
- Medulloblastoma
- Interventions
- Procedure: Surgical resectionOther: Educational and Media InterventionOther: SOC, Educational and Media InterventionProcedure: Ommaya/VPSRadiation: Irradiation
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05535166
- Locations
- 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States
Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
- Conditions
- Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
- Interventions
- Procedure: Pars plana vitrectomy with or without scleral buckle
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 50
- Registration Number
- NCT05523869
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
- Conditions
- Pediatric Brain TumorPediatric Solid Tumor
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT05521984
- Locations
- 🇺🇸
Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri, United States
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT05429502
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
🇺🇸Levine Childrens Hospital, Charlotte, North Carolina, United States
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Extensive Stage Lung Small Cell CarcinomaLimited Stage Lung Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaPlatinum-Resistant Lung Small Cell CarcinomaPlatinum-Sensitive Lung Small Cell CarcinomaRecurrent Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed Tomography
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT05353439
- Locations
- 🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 64
- Registration Number
- NCT05303727
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
- Conditions
- Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian High Grade Serous Adenocarcinoma
- Interventions
- Procedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05295589
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.